Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients

NOBUYUKI GENKAI, JUMPEI HOMMA, MASAKAZU SANO, RYUICHI TANAKA and RYUYA YAMANAKA

Department of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi-dori, Niigata 951-8585, Japan

Received January 3, 2006; Accepted February 23, 2006

Abstract. Pituitary tumor-transforming gene (PTTG), which is homologous to a mammalian securin, plays a pivotal role in cell transformation and is overexpressed in numerous cancer cell lines and tissues. PTTG functions in the control of mitosis, cell transformation, DNA repair and gene regulation. In the present study, we investigated whether the expression of PTTG1 is correlated with tumorigenicity and prognosis in glioma patients. Expression of PTTG1 was confirmed in three glioma cell lines at the mRNA and protein levels using RT-PCR analysis and Western blotting, respectively. Furthermore, PTTG1 protein was detected in 44 glioma tissue samples using immunohistochemical techniques, markedly increased in high-grade gliomas compared to low-grade gliomas and associated with an unfavorable patient outcome. Moreover, siRNA against the PTTG1 gene inhibited cell proliferation and invasion in glioma cell lines. These data suggest that increased expression of PTTG1 contributes to the tumorigenicity of glioma cells and may be useful as a prognostic marker for glioma patients.

Introduction

Glioblastoma is an ordinary solid tumor with a poor prognosis, and even with recent advances in cancer diagnostic methodologies and treatments, the prognosis for glioblastoma patients worldwide has not improved (1,2). This poor prognosis is attributable to the difficulty associated with early detection as well as a high recurrence rate during post-initial treatment observation periods, and is at least partly due to the lack of reliable tumor markers for, and molecular targets against, glioblastomas.

Pituitary tumor-transforming gene (PTTG), the human homolog of securin, was originally identified in rat pituitary tumor cells by differential mRNA display polymerase chain reaction (PCR) (3). Soon thereafter, the human gene for this proto-oncogene was cloned from the human testis (4). The human PTTG family consists of at least three homologous genes (5). Human PTTG1 is located on chromosome 5q33 (6) and its cDNA encodes a protein of 203 amino acids that is predominantly located in the cytoplasm with partial nuclear localization (7). With the exception of the testis and thymus, the levels of PTTG1 mRNA are either low or undetectable in normal adult human tissues (8). However, PTTG1 expression is highly activated in rapidly proliferating cells and various tumors, such as pituitary (9-11), colon (12), thyroid (13,14), ovarian (15), breast (16), testicular (15) and hematopoietic (17) neoplasms. PTTG1 is a multifunctional human securin with roles in the control of mitosis (7,18,19), cell transformation (3,8), DNA repair (20), gene regulation (8,21,22) and fetal development (23). The PTTG2 gene, which is located on chromosome 4p12, is expressed in most normal and tumor tissues, while the PTTG3 gene, which is on chromosome 8q13.1, is only expressed in ovarian tumors and ovarian tumor cell lines (5,6). The detailed mechanism by which PTTG1 induces cellular transformation remains unknown, and the functions of PTTG2 and PTTG3 also remain to be elucidated (5).

In the present study, we investigated the expression of PTTG1 in 44 glioma tissue specimens of different grades, and then examined whether or not increased expression of PTTG1 correlated with patient prognosis.

Materials and methods

Cell lines and culture. The T98G, ON12 and U251 glioma cell lines were purchased from the Cell Bank of the RIKEN BioResource Center (Tsukuba, Japan) and cultured in minimal essential medium (MEM; Nissui Pharmaceutical Inc., Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS).

Patient characteristics and tissue samples. A total of 44 glioma tissue samples were obtained surgically from patients at the Department of Neurosurgery, Brain Research Institute, Niigata University, and were investigated. The glioma tissue and normal brain tissue specimens were dissected and immediately frozen at -80°C. The patient data are shown in Table I. After surgical resection of their tumors, patients with a high-grade glioma received a course of external beam radiation therapy (standard doses:
Table I. Patient’s characteristics.

<table>
<thead>
<tr>
<th>Pathological diagnosis</th>
<th>Number of cases</th>
<th>Gender (male/female)</th>
<th>Age (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astrocytoma</td>
<td>9</td>
<td>7/2</td>
<td>40.7±16.2</td>
</tr>
<tr>
<td>Anaplastic astrocytoma</td>
<td>9</td>
<td>4/5</td>
<td>39.6±15.3</td>
</tr>
<tr>
<td>Glioblastoma</td>
<td>26</td>
<td>17/9</td>
<td>53.0±17.6</td>
</tr>
<tr>
<td>Total</td>
<td>44</td>
<td>28/16</td>
<td>48.0±18.0</td>
</tr>
</tbody>
</table>

Extraction of proteins. Stored samples were crushed in liquid nitrogen and homogenized in RIPA buffer [50 mM Tris-HCl pH 7.4, 1% Nonidet P-40, 0.25% deoxycholate, 150 mM NaCl, 1 mM EGTA and 0.2% sodium dodecyl sulfate (SDS)] containing the following kinase, phosphatase and protease inhibitors: 1 mM NaVO₃, 1 mM NaF, 1 mM Na₂MoO₄, 10 nM okadaic acid, 1 μg/ml benzamide and aprotinin (all from Sigma, Tokyo, Japan). Following incubation on ice for 15 min, the supernatants were removed and stored at -80°C until analysis.

Immunoblotting. Aliquots (100 μg) of the extracted proteins mixed with sample buffer containing 2-mercaptoethanol were separated by 5-20% SDS-PAGE (Bio-Rad Laboratories, Hercules, CA) and transferred to a nitrocellulose membrane (Bio-Rad Laboratories). The membrane was blocked with 5% skim milk in Tris-buffered saline overnight and then incubated with a primary antibody against PTTG1 (Santa Cruz Biotechnology, Santa Cruz, CA). An anti-β-actin mouse monoclonal antibody (Santa Cruz Biotechnology) was used as an internal control. Immunodetection was performed using a horseradish peroxidase detection system with ECL plus (Amersham, Tokyo, Japan).

Immunohistochemistry. Five-micron sections of the formalin-fixed paraffin-embedded tissue specimens were deparaffinized in xylene and dehydrated in a graded ethanol series, followed by phosphate-buffered saline (PBS). The sections were subjected to antigen retrieval by incubation in 10 mM sodium citrate (pH 6.0) at 121°C for 10 min and then incubated in 0.3% H₂O₂ to quench the endogenous peroxidase activity. Next, the sections were blocked in 10% goat serum and incubated with a goat polyclonal anti-PTTG1 antibody (1:20 dilution; Santa Cruz Biotechnology) for 12 h at 4°C. After washing, the sections were incubated with an avidin-biotin-peroxidase system (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA) and then exposed to 0.01% 3,3-diaminobenzidine (DAB; Sigma) in PBS containing 0.01% hydrogen peroxide for 10-20 min. Finally, the sections were examined under a light microscope at an original magnification of x400, and the intensity and area of positive cells were recorded for each immunostained specimen. At this time, the observers were blind to the case numbers. The expression of PTTG1 was evaluated by assigning an immunohistochemical score, defined as the staining intensity (0, none; 1, weak; 2, moderate; 3, strong) and the weighted average (sum of points x area %) of the expression.

RNA isolation and quantitative PCR. Total RNA was isolated from the U251 cell line and used as a template for first-strand cDNA synthesis with oligo(dT) primers and reverse transcriptase (SuperScript II RNase H; Life Technologies, Grand Island, NY) according to the manufacturer’s instructions. Next, quantitative real-time PCR was performed using a LightCycler (Roche Molecular Biochemicals, Mannheim, Germany), 0.5 μM of each primer, 3 mM MgCl₂ and 2μl of cDNA template. The PCR conditions were as follows: 1 cycle of denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, 55°C for 5 sec and 72°C for 10 sec. The 352-bp PCR product was then subjected to a post-PCR melting cycle. The sensitivity of fluorescence was calculated at each cycle, and compared to a standard curve constructed using 4-fold serial dilutions of PTTG1 cDNAs obtained from glioma cell lines. The primer sequences for the PCR amplification were as follows: PTTG1 sense, 5'-AGT TTC AAC ACC ACG TTT TCT CCT CG-3'; PTTG1 antisense, 5'-GCT TTT CAA GCT CTC TCT CCT CG-3'.

SiRNA treatment and cell proliferation assay. A specific siRNA directed against human PTTG was purchased from Qiagen Inc. (Tokyo, Japan). For PTTG RNA silencing, we first tested two different siRNA oligonucleotide sequences, designated PTTG1.1 and PTTG1.2 (25). The sense and antisense sequences used were: PTTG1.1: sense, 5'-GAU CUC AAG UUUCAA CAC CAC Ctt-3' and antisense, 5'-GGU GUU TTT UUA CCA GGA CUA CUA CG-3'; PTTG1.2: sense, 5'-AGT TTC AAC ACC ACG TTT TCT CCT CG-3'; PTTG1 antisense, 5'-GCT TTT CAA GCT CTC TCT CCT CG-3'.
was confirmed using the Cy3-labeled siRNA LUC in each

The transfection efficiency of the PTTG1 gene in U251 cells by quantitative real-time PCR. We compared the expression levels of the PTTG1 gene in U251, ON12 and T98G cells by Western blotting. As shown in Fig. 3, a 28-kDa product was expressed in all three glioma cell lines. Furthermore, β-actin protein, which served as a control, was expressed at 42 kDa.

Table II. Correlation of immunohistochemical pattern and pathological diagnosis.

<table>
<thead>
<tr>
<th></th>
<th>0, none</th>
<th>1, weak</th>
<th>2, moderate</th>
<th>3, strong</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astrocytoma</td>
<td>0</td>
<td>5</td>
<td>4</td>
<td>0.00±0.6</td>
</tr>
<tr>
<td>Anaplastic</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>0.00±0.6</td>
</tr>
<tr>
<td>Glioblastoma</td>
<td>0</td>
<td>1</td>
<td>17</td>
<td>2.00±0.6</td>
</tr>
</tbody>
</table>

*P<0.05.

Table III. Correlation of immunohistochemical score and pathological diagnosis.

<table>
<thead>
<tr>
<th></th>
<th>0-1</th>
<th>1-2</th>
<th>2-3</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astrocytoma</td>
<td>6</td>
<td>3</td>
<td>0</td>
<td>0.65±0.6</td>
</tr>
<tr>
<td>Anaplastic</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td>0.81±0.6</td>
</tr>
<tr>
<td>Glioblastoma</td>
<td>11</td>
<td>14</td>
<td>1</td>
<td>1.17±0.64</td>
</tr>
</tbody>
</table>

**P<0.05.

Statistics. The differences in PTTG1 expression between the glioma subgroups were tested for statistical significance using the Mann-Whitney U test. Statistical significance was determined at the P<0.05 level. Survival curves were estimated according to the method of Kaplan and Meier and compared using the generalized Wilcoxon test. The log-rank test was used to assess the strength of associations between the survival time and single variables corresponding to factors thought to be prognostic for survival.

Results

Immunohistochemical analysis of PTTG1 expression in glioma tissue. Immunohistochemistry was carried out to detect the localization of PTTG1 protein in glioma tissue, and the immunostaining pattern is shown in Fig. 1. PTTG1 expression was detected in the nucleus of the tumor cells, revealing that activated transcription factors had translocated into the nucleus. We analyzed the 44 available specimens and investigated the correlations among PTTG1 staining, patient survival and histological grading. Glioblastoma patients (26 cases) showed strong staining in comparison with grade-2 and -3 patients (18 cases) (Table II; P=0.03). Similarly, glioblastoma patients showed a high immunohistochemical score compared with grade-2 and -3 patients (Table III; P=0.02). When the high immunohistochemical score group was compared with the low immunohistochemical score group, increased PTTG1 expression was correlated with patient survival in astrocytoma plus anaplastic astrocytoma cases (Fig. 2A; log-rank test, P=0.70), anaplastic astrocytoma plus glioblastoma cases (Fig. 2B; log-rank test, P=0.01), glioblastoma cases (Fig. 2C; log-rank test, P=0.03) and all glioma cases (Fig. 2D; log-rank test, P=0.003).

PTTG1 protein expression in glioma cells evaluated by Western blotting. We analyzed the expression of PTTG1 protein in U251, ON12 and T98G cells by Western blotting. As shown in Fig. 3, a 28-kDa product was expressed in all three glioma cell lines. Furthermore, β-actin protein, which served as a control, was expressed at 42 kDa.

PTTG1 mRNA expression is inhibited in glioma cells by PTTG1 siRNA transfection. We compared the expression levels of the PTTG1 gene in U251 cells by quantitative real-time

Statistics. The differences in PTTG1 expression between the glioma subgroups were tested for statistical significance using the Mann-Whitney U test. Statistical significance was determined at the P<0.05 level. Survival curves were estimated according to the method of Kaplan and Meier and compared using the generalized Wilcoxon test. The log-rank test was used to assess the strength of associations between the survival time and single variables corresponding to factors thought to be prognostic for survival.

Results

Immunohistochemical analysis of PTTG1 expression in glioma tissue. Immunohistochemistry was carried out to detect the localization of PTTG1 protein in glioma tissue, and the immunostaining pattern is shown in Fig. 1. PTTG1 expression was detected in the nucleus of the tumor cells, revealing that activated transcription factors had translocated into the nucleus. We analyzed the 44 available specimens and investigated the correlations among PTTG1 staining, patient survival and histological grading. Glioblastoma patients (26 cases) showed strong staining in comparison with grade-2 and -3 patients (18 cases) (Table II; P=0.03). Similarly, glioblastoma patients showed a high immunohistochemical score compared with grade-2 and -3 patients (Table III; P=0.02). When the high immunohistochemical score group was compared with the low immunohistochemical score group, increased PTTG1 expression was correlated with patient survival in astrocytoma plus anaplastic astrocytoma cases (Fig. 2A; log-rank test, P=0.70), anaplastic astrocytoma plus glioblastoma cases (Fig. 2B; log-rank test, P=0.01), glioblastoma cases (Fig. 2C; log-rank test, P=0.03) and all glioma cases (Fig. 2D; log-rank test, P=0.003).

PTTG1 protein expression in glioma cells evaluated by Western blotting. We analyzed the expression of PTTG1 protein in U251, ON12 and T98G cells by Western blotting. As shown in Fig. 3, a 28-kDa product was expressed in all three glioma cell lines. Furthermore, β-actin protein, which served as a control, was expressed at 42 kDa.

PTTG1 mRNA expression is inhibited in glioma cells by PTTG1 siRNA transfection. We compared the expression levels of the PTTG1 gene in U251 cells by quantitative real-time

Statistics. The differences in PTTG1 expression between the glioma subgroups were tested for statistical significance using the Mann-Whitney U test. Statistical significance was determined at the P<0.05 level. Survival curves were estimated according to the method of Kaplan and Meier and compared using the generalized Wilcoxon test. The log-rank test was used to assess the strength of associations between the survival time and single variables corresponding to factors thought to be prognostic for survival.

Results

Immunohistochemical analysis of PTTG1 expression in glioma tissue. Immunohistochemistry was carried out to detect the localization of PTTG1 protein in glioma tissue, and the immunostaining pattern is shown in Fig. 1. PTTG1 expression was detected in the nucleus of the tumor cells, revealing that activated transcription factors had translocated into the nucleus. We analyzed the 44 available specimens and investigated the correlations among PTTG1 staining, patient survival and histological grading. Glioblastoma patients (26 cases) showed strong staining in comparison with grade-2 and -3 patients (18 cases) (Table II; P=0.03). Similarly, glioblastoma patients showed a high immunohistochemical score compared with grade-2 and -3 patients (Table III; P=0.02). When the high immunohistochemical score group was compared with the low immunohistochemical score group, increased PTTG1 expression was correlated with patient survival in astrocytoma plus anaplastic astrocytoma cases (Fig. 2A; log-rank test, P=0.70), anaplastic astrocytoma plus glioblastoma cases (Fig. 2B; log-rank test, P=0.01), glioblastoma cases (Fig. 2C; log-rank test, P=0.03) and all glioma cases (Fig. 2D; log-rank test, P=0.003).

PTTG1 protein expression in glioma cells evaluated by Western blotting. We analyzed the expression of PTTG1 protein in U251, ON12 and T98G cells by Western blotting. As shown in Fig. 3, a 28-kDa product was expressed in all three glioma cell lines. Furthermore, β-actin protein, which served as a control, was expressed at 42 kDa.

PTTG1 mRNA expression is inhibited in glioma cells by PTTG1 siRNA transfection. We compared the expression levels of the PTTG1 gene in U251 cells by quantitative real-time

Statistics. The differences in PTTG1 expression between the glioma subgroups were tested for statistical significance using the Mann-Whitney U test. Statistical significance was determined at the P<0.05 level. Survival curves were estimated according to the method of Kaplan and Meier and compared using the generalized Wilcoxon test. The log-rank test was used to assess the strength of associations between the survival time and single variables corresponding to factors thought to be prognostic for survival.

Results

Immunohistochemical analysis of PTTG1 expression in glioma tissue. Immunohistochemistry was carried out to detect the localization of PTTG1 protein in glioma tissue, and the immunostaining pattern is shown in Fig. 1. PTTG1 expression was detected in the nucleus of the tumor cells, revealing that activated transcription factors had translocated into the nucleus. We analyzed the 44 available specimens and investigated the correlations among PTTG1 staining, patient survival and histological grading. Glioblastoma patients (26 cases) showed strong staining in comparison with grade-2 and -3 patients (18 cases) (Table II; P=0.03). Similarly, glioblastoma patients showed a high immunohistochemical score compared with grade-2 and -3 patients (Table III; P=0.02). When the high immunohistochemical score group was compared with the low immunohistochemical score group, increased PTTG1 expression was correlated with patient survival in astrocytoma plus anaplastic astrocytoma cases (Fig. 2A; log-rank test, P=0.70), anaplastic astrocytoma plus glioblastoma cases (Fig. 2B; log-rank test, P=0.01), glioblastoma cases (Fig. 2C; log-rank test, P=0.03) and all glioma cases (Fig. 2D; log-rank test, P=0.003).

PTTG1 protein expression in glioma cells evaluated by Western blotting. We analyzed the expression of PTTG1 protein in U251, ON12 and T98G cells by Western blotting. As shown in Fig. 3, a 28-kDa product was expressed in all three glioma cell lines. Furthermore, β-actin protein, which served as a control, was expressed at 42 kDa.

PTTG1 mRNA expression is inhibited in glioma cells by PTTG1 siRNA transfection. We compared the expression levels of the PTTG1 gene in U251 cells by quantitative real-time
we synthesized siRNAs that targeted PTTG1 mRNA for degradation following their transfection into cells, thereby reducing the expression of PTTG1 mRNA. We analyzed the efficacy of the siRNA-mediated inhibition of PTTG1 expression in U251 cells. After transfection with the PTTG1 siRNA, the PTTG1 mRNA levels over the ensuing 48 h were ~16% of the levels in untreated or control siRNA-treated cells during the same time period (Fig. 4A; P<0.05).

Glioma cell proliferation and invasion are inhibited by PTTG1 siRNA transfection. PTTG1 overexpression was linked with the aggressiveness of the glioma in our analysis. In order to determine whether downregulation of endogenous PTTG1 would suppress the proliferation and invasive behavior of gliomas, we used the above-mentioned siRNAs that targeted PTTG1 mRNA for degradation, thereby reducing the expression of PTTG1 protein. The efficacy of the siRNA-mediated inhibition of PTTG1 protein synthesis was analyzed in U251, ON12 and T98G cells. After transfection with the PTTG1 siRNA, the U251 cell counts over the ensuing 48 h were ~60% of the levels of untreated or control siRNA-treated cells during the same time period (Fig. 4B; P<0.05). For invasion assays, the transfectants were seeded onto Matrigel-coated invasion chambers and incubated for 24 h, before the total number of cells on the underside of each filter was determined. As shown in Fig. 4C, transfection of U251 cells with the PTTG1 siRNA inhibited cell invasion through the Matrigel by >30%, whereas the control siRNA had no effect (P<0.01). Invading cells were significantly suppressed by the siRNA against PTTG1, as reflected in the observed reductions of mRNA expression. Since the results obtained were virtually identical for all three cell types, only those for one cell type are presented.

Discussion

Malignant gliomas are the most common primary brain tumors and are generally considered to be one of the deadliest human cancers. Glioblastoma multiforme, which is pathologically the
The MAP kinase cascade and c-Myc have been suggested thereby supporting the role of PTTG1 in cell growth regulation. Expression of PTTG1 results in increased cell proliferation, conditions (30). Induction of c-myc expression by over-differentiation and induces apoptosis under low-serum stimulation of human glioma cells. U251 cells were transiently transfected with siRNAs and subjected to cell proliferation assays. After transfection with the PTTG1 siRNA, the U251 cell counts over the ensuing 48 h are approximately 60% of the levels in the untreated or control siRNA-treated cells during the same time period. *P<0.05 compared with both control groups. (C) For the invasion assays, the transfecants were seeded onto Matrigel-coated invasion chambers and incubated for 24 h, before the total number of cells on the underside of each filter was determined. Invading cells are significantly suppressed by the siRNA against PTTG1, as reflected in the observed reduction of protein expression. **P<0.01 compared with both control groups.

Figure 4. (A) Effects of a PTTG1 siRNA on PTTG1 mRNA expression in human glioma cell lines. After transfection with the PTTG1 siRNA, the PTTG1 mRNA levels over the ensuing 48 h are significantly suppressed to ~16% of the levels in the untreated or control siRNA-treated cells during the same time period. (B) Effects of PTTG1 protein knockdown by a PTTG1 siRNA on the proliferation of human glioma cells. U251 cells were transiently transfected with PTTG1 siRNA and subjected to cell proliferation assays. After transfection with the PTTG1 siRNA, the cell proliferation over the ensuing 48 h are significantly suppressed to ~16% of the levels in the untreated or control siRNA-treated cells during the same time period. *P<0.05 compared with both control groups. (C) For the invasion assays, the transfected cells were seeded onto Matrigel-coated invasion chambers and incubated for 24 h, before the total number of cells on the underside of each filter was determined. Invading cells are significantly suppressed by the siRNA against PTTG1, as reflected in the observed reduction of protein expression. **P<0.01 compared with both control groups.

Overexpression of PTTG1 has been identified in many cancers as well as in cell lines representing pituitary, colon, thyroid, testicular, ovarian, breast and various other solid tumors. PTTG1 mRNA expression has been reported to serve as a marker for lymph node invasion in colon cancer (12) and tumor recurrence in primary breast cancer (16).

Although the mechanisms involved in PTTG cellular transformation and tumorigenesis remain to be elucidated, several reports have described the role of PTTG1 in tumor progression. First, PTTG1 expression was reported to be cell cycle-dependent, being lowest at the G1-/S-phase border, gradually increasing during S-phase and peaking at the G2/M-phases (7). PTTG functions as a regulator of separin, an enzyme that degrades cohesin during anaphase, and maintains sister chromatid binding (18,27) to prevent premature chromosome separation through inhibition of separase activity. Overexpression of PTTG1 induces aneuploidy in live cells via chromatin missegregation (28), enhances cell proliferation, induces cellular transformation and promotes tumor formation in nude mice (8,29). Second, c-myc was reported to be a downstream target for PTTG1. Overexpression of c-myc protein stimulates cell cycle progression, causes transformation, blocks differentiation and induces apoptosis under low-serum conditions (30). Induction of c-myc expression by over-expression of PTTG1 results in increased cell proliferation, thereby supporting the role of PTTG1 in cell growth regulation (31). The MAP kinase cascade and c-Myc have been suggested to be involved in PTTG-mediated cell proliferation. Third, PTTG1 was reported to induce angiogenesis through the angiogenic factor basic fibroblast growth factor (bFGF), which is a significant factor for tumor progression (32).

The relationships between PTTG and the clinical features of gliomas have not previously been described. In the current study, we have presented data concerning the expression of PTTG1 in glioma cell lines and tissues, and shown that PTTG1 protein is overexpressed in high-grade astrocytomas compared to low-grade astrocytomas. On the basis of our data, PTTG1 may potentially play a role in the proliferation and invasiveness of glioma cells. Therefore, PTTG1 may be a novel molecular target for therapy as well as an important predictive marker for survival in glioma patients.

Acknowledgments

We are grateful to N. Kiyama and F. Higuchi for their excellent technical assistance.

References


